| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm |
| Cash burn (monthly) | (no burn) | 488.20 k | 922.83 k | 932.66 k | 814.91 k | 909.81 k |
| Cash used (since last report) | n/a | 1.18 mm | 2.23 mm | 2.25 mm | 1.97 mm | 2.20 mm |
| Cash remaining | n/a | 221.83 k | -828.75 k | -852.50 k | -567.88 k | -797.28 k |
| Runway (months of cash) | n/a | 0.5 | -0.9 | -0.9 | -0.7 | -0.9 |
| 13F holders | Current |
|---|---|
| Total holders | 11 |
| Opened positions | 9 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 64.42 mm |
| Total shares | 2.86 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Alpha 18 | 1.50 mm | $341.00 k |
| L1 Capital Global Opportunities Master Fund | 776.38 k | $908.00 k |
| CVI Investments | 400.53 k | $204.00 k |
| Warberg Asset Management | 48.80 k | $26.50 mm |
| Bayer Healthcare | 48.32 k | $25.00 k |
| Two Sigma Securities | 34.16 k | $18.55 mm |
| Geode Capital Management | 27.10 k | $14.72 mm |
| Virtu Financial | 21.31 k | $12.00 k |
| NA.R National Bank of Canada | 5.00 k | $2.72 mm |
| Tower Research Capital | 799.00 | $434.00 k |
